ProCE Banner Activity

QUAZAR AML-001 Phase III Trial of Oral AZA (CC-486) vs Placebo as Maintenance Therapy in AML After First Remission: Analyses by MRD Status

Slideset Download
Conference Coverage
Oral AZA (CC-486) significantly improved OS and RFS in patients with CR/CRi AML regardless of baseline MRD status, although baseline MRD positivity showed reduced benefit.

Released: December 14, 2020

Expiration: December 13, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology